1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Swedish Orphan Biovitrum AB (publ)
  6. Summary
    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM AB (PUBL)

(SOBI)
  Report
Delayed Nasdaq Stockholm  -  11:29 2022-06-23 am EDT
217.30 SEK   +0.05%
06/10Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Efficacy and Safety Profile of EMPAVELI (pegcetacoplan) for PNH at EHA 2022 Congress
CI
06/08Sobi, Apellis Start Dosing Patients in Late-Stage Trial of Rare Kidney Disease Treatment
MT
06/07Sobi, Apellis Dose First Patient In Phase 3 Study Of Pegcetacoplan For Rare Kidney Diseases
MT
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Stockholm
06/17/2022 06/20/2022 06/21/2022 06/22/2022 06/23/2022 Date
211.1(c) 213.6(c) 214.9(c) 217.2(c) 217.3(c) Last
1 452 892 231 482 789 722 672 890 362 533 Volume
+2.03% +1.18% +0.61% +1.07% +0.05% Change
More quotes
Estimated financial data (e)
Sales 2022 17 499 M 1 728 M 1 728 M
Net income 2022 2 342 M 231 M 231 M
Net Debt 2022 6 507 M 643 M 643 M
P/E ratio 2022 28,1x
Yield 2022 -
Sales 2023 18 710 M 1 848 M 1 848 M
Net income 2023 3 285 M 324 M 324 M
Net Debt 2023 2 124 M 210 M 210 M
P/E ratio 2023 19,6x
Yield 2023 -
Capitalization 64 137 M 6 334 M 6 334 M
EV / Sales 2022 4,04x
EV / Sales 2023 3,54x
Nbr of Employees 1 569
Free-Float 57,8%
More Financials
Company
Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the... 
Sector
Pharmaceuticals
Calendar
07/19 | 02:00amEarnings Release
More about the company
Ratings of Swedish Orphan Biovitrum AB (publ)
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B+
More Ratings
All news about SWEDISH ORPHAN BIOVITRUM AB (PUBL)
06/10Apellis Pharmaceuticals, Inc. and Sobi(R) Report New Data Reinforcing the Robust Effica..
CI
06/08Sobi, Apellis Start Dosing Patients in Late-Stage Trial of Rare Kidney Disease Treatmen..
MT
06/07Sobi, Apellis Dose First Patient In Phase 3 Study Of Pegcetacoplan For Rare Kidney Dise..
MT
06/07Apellis Pharmaceuticals, Inc. and Sobi Announces First Patient Dosed in Phase 3 VALIANT..
CI
06/01Swedish Orphan Biovitrum, Sanofi Secure US FDA's Breakthrough Therapy Designation For H..
MT
06/01FDA grants efanesoctocog alfa Breakthrough Therapy designation for haemophilia A
AQ
05/10Bulletin from Swedish Orphan Biovitrum (Sobi®)'s Annual General Meeting (AGM)
AQ
05/10Swedish Orphan Biovitrum AB Elects Bo Jesper Hansen as New Board Member
CI
04/28Swedish Orphan Biovitrum AB Reports Earnings Results for the First Quarter Ended March ..
CI
04/28TRANSCRIPT : Swedish Orphan Biovitrum AB, Q1 2022 Earnings Call, Apr 28, 2022
CI
04/28Swedish Drugmaker Sobi Confirms FY22 Revenue Outlook After Q1 Growth
MT
04/28Drugmaker Sobi books profit fall on restructuring, Russia
RE
04/28Sobi publishes Q1 2022 report
AQ
04/28Swedish Orphan Biovitrum AB Provides Earnings Guidance for the Year 2022
CI
04/20INVITATION : Sobi's Q1 2022 report
AQ
More news
News in other languages on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
06/10Apellis Pharmaceuticals, Inc. et Sobi(R) présentent de nouvelles données renforçant le ..
06/08Sobi et Apellis commencent à doser les patients dans le cadre d'un essai de stade avanc..
06/07Sobi et Apellis administrent une dose au premier patient de l'étude de phase 3 du pegce..
06/07Apellis Pharmaceuticals, Inc. et Sobi annoncent que le premier patient a reçu une dose ..
06/01POINT SUR LES FORTES VARIATIONS DU J : les investisseurs ont trouvé Doc Martens à leurs pi..
More news
Analyst Recommendations on SWEDISH ORPHAN BIOVITRUM AB (PUBL)
More recommendations
Chart SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Duration : Period :
Swedish Orphan Biovitrum AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SWEDISH ORPHAN BIOVITRUM AB (PUBL)
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 8
Last Close Price 217,30 SEK
Average target price 245,38 SEK
Spread / Average Target 12,9%
EPS Revisions
Managers and Directors
Guido Oelkers President & Chief Executive Officer
Henrik Stenqvist Chief Financial Officer
Sven Håkan Björklund Chairman
Sven Anders Ullman Chief Medical Officer, Head-Research & Development
Christine Wesström Head-Technical Operations
Sector and Competitors